Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : XOMA. Bull or Bear? -- Ignore unavailable to you. Want to Upgrade?

To: aknahow who wrote (5423)	1/29/1998 8:24:00 PM
From: Tharos	Read Replies (1) \| Respond to of 17367

George, You make a great point that when Wall Street's "quarterly" mentality punishes a firm for good/normal business practices it is probably a good time to scoop up at bargin prices. If your outlook is longterm and the fundamentals haven't changed, then short term technical problems should be viewed as opportunity. Personally, I find R&D numbers important in my bio-tech Fundamental Analysis process. If I don't think the numbers are high enough, I don't invest. It is the R&D that develops the break-through product(s) from which we economically benefit as partial owners of the firm.

To: aknahow who wrote (5423)	1/30/1998 4:26:00 PM
From: Starlight	Read Replies (2) \| Respond to of 17367

ON TOPIC: I heard Michael Murphy speak last night. He's got XOMA on his buy list and he feels the stock could hit $45/share by 1999. He said in his talk that even 1 or 2 drugs could build a biotech firm into a "giant". He said the meningo. trials are going very, very well. They have to do 200 patients, and he expects they'll have accrued that many by this summer. He said in his talk (to AAII members) that so far, out of 135 patients in the trial, only 6 have died. I'll post more info later when I have more time. It's wave-watching time here -- we're getting killer waves along the coast today. Betty